Akebia Therapeutics, Inc.AKBANASDAQ

Revenue (LTM)

$236M

+47.5% YoY

Net Income (LTM)

$-5M

+92.3% YoY

Free Cash Flow

$68M

Revenue CAGR (5Y)

-4.3%

Marginsdeclining

FCFTurned positive

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	212	292↑38.2%	195↓33.5%	160↓17.7%	236↑47.5%
Gross Profit	130	270↑107.4%	120↓55.4%	97↓19.5%	197↑102.8%
Operating Income	-265	-81↑69.5%	-46↑42.7%	-50↓9.1%	23↑146.6%
Net Income	-282	-94↑66.6%	-52↑44.9%	-69↓33.7%	-5↑92.3%
EBITDA	-190	3↑101.6%	-8↓370.5%	-14↓66.0%	22↑258.3%
EPS Diluted	-1.48	-0.58↑60.8%	-0.28↑51.7%	-0.33↓17.9%	-0.02↑93.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	150	90↓39.6%	43↓52.6%	52↑20.8%	185↑256.4%
Total Current Assets	271	185↓31.7%	118↓36.2%	114↓3.7%	185↑62.4%
Total Assets	529	356↓32.7%	242↓32.1%	221↓8.7%	377↑70.6%
Total Current Liabilities	261	130↓50.4%	100↓22.9%	81↓19.0%	163↑101.4%
Total Liabilities	455	351↓23.0%	272↓22.4%	270↓0.9%	344↑27.5%
Total Equity	74	5↓92.9%	-31↓684.8%	-49↓60.8%	33↑166.3%
Total Debt	136	100↓26.7%	104↑4.4%	189↑81.2%	216↑14.6%
Net Debt	-14	9↑167.8%	61↑557.5%	137↑123.4%	31↓77.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-253	-73↑71.1%	-23↑68.0%	-41↓73.9%	68↑267.2%
Capital Expenditure	-0	-0↓93.2%	0	-0	-0↓781.8%
Free Cash Flow	-253	-73↑71.0%	-23↑68.1%	-41↓74.0%	68↑267.1%
Stock-Based Comp	0	18	9↓47.8%	8↓16.6%	11↑45.1%
Net Change in Cash	-79	-59↑26.0%	-49↑17.2%	9↑118.5%	133↑1382.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance